首页> 外文期刊>Haematologica >Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome | Haematologica
【24h】

Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome | Haematologica

机译:沙利度胺治疗的多发性骨髓瘤患者:评估临床指标,细胞因子,血管生成标记,肥大细胞和骨髓CD57 +细胞毒性T细胞|血液学

获取原文
           

摘要

Background and Objectives In vitro studies suggest that thalidomide has an immunoregulatory role and alters the marrow microenvironment. We assessed laboratory and clinical parameters in patients with myeloma treated with thalidomide as potential prognostic markers and looked for changes with therapy.
机译:背景与目的体外研究表明,沙利度胺具有免疫调节作用,并能改变骨髓的微环境。我们评估了沙利度胺作为潜在预后指标的骨髓瘤患者的实验室和临床参数,并寻找治疗方法的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号